Inflation Reduction Act & Medicare Part D Public Comments

BACK TO IRA MAIN POLICY PAGE

• RE: Public Submission Form for Information about Selected Drugs and Their Therapeutic Alternatives: BIKTARVY (February 27, 2026)

• RE: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] (February 20, 2026)

• RE: CMS Proposed Exclusion of 340B Drug Units from Medicare Inflation Rebate Calculations [CMS-1832-P; RIN 0938-AV50] (September 5, 2025)

• RE: Sign-On Letter in Support of Medicare Drug Price Negotiation Program Carve-Out Exemption for Medications Indicated for the Treatment of HIV/AIDS (August 20, 2025)

• RE: Written testimony to the Centers for Medicare & Medicaid Services expressing concerns about the 2028 Medicare Drug Price Negotiation Program Draft Guidance, and asking for an HIV carve-out (June 25, 2025)

BACK TO IRA MAIN POLICY PAGE